Search Results - "Amrein, Philip"

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy by Montero, Joan, Sarosiek, Kristopher A., DeAngelo, Joseph D., Maertens, Ophélia, Ryan, Jeremy, Ercan, Dalia, Piao, Huiying, Horowitz, Neil S., Berkowitz, Ross S., Matulonis, Ursula, Jänne, Pasi A., Amrein, Philip C., Cichowski, Karen, Drapkin, Ronny, Letai, Anthony

“…There is a lack of effective predictive biomarkers to precisely assign optimal therapy to cancer patients. While most efforts are directed at inferring drug…”
Get full text

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study by Savona, Michael R, Odenike, Olatoyosi, Amrein, Philip C, Steensma, David P, DeZern, Amy E, Michaelis, Laura C, Faderl, Stefan, Harb, Wael, Kantarjian, Hagop, Lowder, James, Oganesian, Aram, Azab, Mohammad, Garcia-Manero, Guillermo

“…Decitabine, a DNA methyltransferase 1 inhibitor or DNA hypomethylating compound, is not readily orally bioavailable because of rapid clearance by cytidine…”
Get full text

Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia by El‐Jawahri, Areej R., Abel, Gregory A., Steensma, David P., LeBlanc, Thomas W., Fathi, Amir T., Graubert, Timothy A., DeAngelo, Daniel J., Wadleigh, Martha, Ballen, Karen K., Foster, Julia E., Attar, Eyal C., Amrein, Philip C., Brunner, Andrew M., Stone, Richard M., Temel, Jennifer S.

“…BACKGROUND Health care utilization in older adults (age ≥60 years) with acute myeloid leukemia (AML) has not been well studied. METHODS We conducted a…”
Get full text

Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia by Fathi, Amir T, Kim, Haesook T, Soiffer, Robert J, Levis, Mark J, Li, Shuli, Kim, Annette S, DeFilipp, Zachariah, El-Jawahri, Areej, McAfee, Steve L, Brunner, Andrew M, Amrein, Philip C, Mims, Alice S, Knight, Laura W, Kelley, Devon, Bottoms, Aj S, Perry, Lindsey H, Wahl, Jonathan L, Brock, Jennifer, Breton, Elayne, Marchione, Dylan M, Ho, Vincent T, Chen, Yi-Bin

“…Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use…”
Get full text

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502 by ATTAR, Eyal C, JOHNSON, Jeffrey L, BLUM, William, STONE, Richard M, MARCUCCI, Guido, BLOOMFIELD, Clara D, MOSER, Barry, LARSON, Richard A, AMREIN, Philip C, LOZANSKI, Gerard, WADLEIGH, Martha, DEANGELO, Daniel J, KOLITZ, Jonathan E, POWELL, Bayard L, VOORHEES, Peter, WANG, Eunice S

“…The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated…”
Get full text

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response by Fathi, Amir T., Sadrzadeh, Hossein, Borger, Darrell R., Ballen, Karen K., Amrein, Philip C., Attar, Eyal C., Foster, Julia, Burke, Meghan, Lopez, Hector U., Matulis, Christina R., Edmonds, Katherine M., Iafrate, A. John, Straley, Kimberly S., Yen, Katharine E., Agresta, Samuel, Schenkein, David P., Hill, Cedric, Emadi, Ashkan, Neuberg, Donna S., Stone, Richard M., Chen, Yi-Bin

“…Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recently described in acute myeloid leukemia (AML). Serum and myeloblast samples…”
Get full text

Case 33-2021: A 68-Year-Old Man with Painful Mouth Ulcers by Woo, Sook-Bin, Wu, Markus Y, Treister, Nathaniel S, Amrein, Philip C, Kroshinsky, Daniela, Hasserjian, Robert P

“…A 68-year-old man was admitted with painful mouth ulcers and weight loss of 6 weeks’ duration. The ulcers had worsened despite treatment with acyclovir,…”
Get full text

Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia by AMREIN, Philip C, ATTAR, Eyal C, HASSERJIAN, Robert P, WERNER, Lillian, NEUBERG, Donna, BROWN, Jennifer R, TAKVORIAN, Tak, HOCHBERG, Ephraim P, BALLEN, Karen K, LEAHY, Kathleen M, FISHER, David C, LACASCE, Ann S, JACOBSEN, Eric D, ARMAND, Philippe

“…Chronic lymphocytic leukemia (CLL) cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the…”
Get full text

Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population‐based study by Perry, Ashley M., Brunner, Andrew M., Zou, Tao, McGregor, Kristin L., Amrein, Philip C., Hobbs, Gabriela S., Ballen, Karen K., Neuberg, Donna S., Fathi, Amir T.

“…BACKGROUND Chronic myeloid leukemia (CML) can be treated effectively with tyrosine kinase inhibitor therapy directed at BCR‐ABL, but access to care, medication…”
Get full text

Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy by Nardi, Valentina, McAfee, Steven L, Dal Cin, Paola, Tsai, Harrison K, Amrein, Philip C, Hobbs, Gabriela S, Brunner, Andrew M, Narayan, Rupa, Foster, Julia, Fathi, Amir T, Hock, Hanno

“…BCR-ABL1 kinase inhibitors have improved the prognosis of Philadelphia-chromosome-positive (Ph+)-acute lymphoblastic leukemia (ALL). Ph-like (or BCR-ABL1-like)…”
Get full text

The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms by Amrein, Philip C.

“…Dasatinib is a kinase inhibitor that inhibits BCR-ABL, Src family kinases, c-Kit, and platelet-derived growth factor receptor kinase. It is licensed for the…”
Get full text

Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia by Brunner, Andrew M., Neuberg, Donna S., Wander, Seth A., Sadrzadeh, Hossein, Ballen, Karen K., Amrein, Philip C., Attar, Eyal, Hobbs, Gabriela S., Chen, Yi‐Bin, Perry, Ashley, Connolly, Christine, Joseph, Christelle, Burke, Meghan, Ramos, Aura, Galinsky, Ilene, Yen, Katharine, Yang, Hua, Straley, Kimberly, Agresta, Sam, Adamia, Sophia, Borger, Darrell R., Iafrate, Anthony, Graubert, Timothy A., Stone, Richard M., Fathi, Amir T.

“…Background Acute myeloid leukemia (AML) cells harboring mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) produce the…”
Get full text

Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission by Slavin, Samuel D., Fenech, Alyssa, Jankowski, Amanda L., Abel, Gregory A., Brunner, Andrew M., Steensma, David P., Fathi, Amir T., DeAngelo, Daniel J., Wadleigh, Martha, Hobbs, Gabriela S., Amrein, Philip C., Stone, Richard M., Temel, Jennifer S., El‐Jawahri, Areej

“…Background Older adults with acute myeloid leukemia (AML) are often assumed to have poor outcomes after admission to the intensive care unit (ICU). However,…”
Get full text

Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia by Emadi, Ashkan, Law, Jennie Y., Strovel, Erin T., Lapidus, Rena G., Jeng, Linda J. B., Lee, Myounghee, Blitzer, Miriam G., Carter-Cooper, Brandon A., Sewell, Danielle, Van Der Merwe, Isabella, Philip, Sunita, Imran, Mohammad, Yu, Stephen L., Li, Hongxia, Amrein, Philip C., Duong, Vu H., Sausville, Edward A., Baer, Maria R., Fathi, Amir T., Singh, Zeba, Bentzen, Søren M.

“…Depletion of glutamine (Gln) has emerged as a potential therapeutic approach in the treatment of acute myeloid leukemia (AML), as neoplastic cells require Gln…”
Get full text

Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis by Movassaghian, Maryam, Brunner, Andrew M., Blonquist, Traci M., Sadrzadeh, Hossein, Bhatia, Ashmeet, Perry, Ashley M., Attar, Eyal C., Amrein, Philip C., Ballen, Karen K., Neuberg, Donna S., Fathi, Amir T.

“…Abstract Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its…”
Get full text

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation by Fathi, Amir T., Blonquist, Traci M., Hernandez, Daniela, Amrein, Philip C., Ballen, Karen K., McMasters, Malgorzata, Avigan, David E., Joyce, Robin, Logan, Emma K., Hobbs, Gabriela, Brunner, Andrew M., Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Behnan, Tanya, Foster, Julia, Bergeron, Meghan K., Moran, Jenna A., Ramos, Aura Y., Som, Tina T., Rae, Jessica, Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Levis, Mark J.

“…BACKGROUND Cabozantinib, a tyrosine kinase inhibitor of FMS‐like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is…”
Get full text

A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia by Narayan, Rupa, Blonquist, Traci M., Emadi, Ashkan, Hasserjian, Robert P., Burke, Meghan, Lescinskas, Christopher, Neuberg, Donna S., Brunner, Andrew M., Hobbs, Gabriela, Hock, Hanno, McAfee, Steven L., Chen, Yi‐Bin, Attar, Eyal, Graubert, Timothy A., Bertoli, Christina, Moran, Jenna A., Bergeron, Meghan K., Foster, Julia E., Ramos, Aura Y., Som, Tina T., Vartanian, Megan K., Story, Jennifer L., McGregor, Kristin, Macrae, Molly, Behnan, Tanya, Wey, Margaret C., Rae, Jessica, Preffer, Frederic I., Lesho, Patricia, Duong, Vu H., Mann, Mason L., Ballen, Karen K., Connolly, Christine, Amrein, Philip C., Fathi, Amir T.

“…Background Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high…”
Get full text

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia by Fathi, Amir T, Wander, Seth A, Blonquist, Traci M, Brunner, Andrew M, Amrein, Philip C, Supko, Jeffrey, Hermance, Nicole M, Manning, Amity L, Sadrzadeh, Hossein, Ballen, Karen K, Attar, Eyal C, Graubert, Timothy A, Hobbs, Gabriela, Joseph, Christelle, Perry, Ashley M, Burke, Meghan, Silver, Regina, Foster, Julia, Bergeron, Meghan, Ramos, Aura Y, Som, Tina T, Fishman, Kaitlyn M, McGregor, Kristin L, Connolly, Christine, Neuberg, Donna S, Chen, Yi-Bin

“…Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia. Alisertib, an aurora A kinase…”
Get full text

Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes by Chen, Evan C., Werner, Lillian, Hobbs, Gabriela S., Narayan, Rupa, Amrein, Philip C., Fathi, Amir T., Brunner, Andrew M.

Get full text

Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy by Venkataraman, Vinayak, Casey, Keagan S., Onozato, Maristela, Cin, Paola Dal, Nardi, Valentina, Amrein, Philip C., Bergeron, Meghan K., Brunner, Andrew M., Fathi, Amir T., Foster, Julia E., Moran, Jenna, Graubert, Timothy A., Hock, Hanno, Hunnewell, Chrisa, Frigault, Matthew J., McAfee, Steven, Hobbs, Gabriela S.

Get full text